<DOC>
	<DOCNO>NCT00405873</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety AMT2003 cancer patient advance primary hepatocellular carcinoma The primary endpoint best overall response rate within 20 week registration</brief_summary>
	<brief_title>Study Evaluate Tumour Response Cancer Patients With Advanced Hepatocellular Carcinoma ( Liver Cancer ) With AMT2003</brief_title>
	<detailed_description>The study include patient advanced primary hepatocellular carcinoma refractory standard therapy effective standard therapy exist . The best overall response rate best response record start treatment disease progression / recurrence .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Cancer confirm histology cytology At least one measurable lesion Advanced disease refractory standard therapy standard therapy exist Life expectancy least 3 month Known secondary neoplasia central nervous system ( CNS ) metastases ; acute chronic leukemia , lymphoma multiple myeloma Body weight 45 kg Female patient pregnant breast feed adult reproductive potential employ effective method birth control Confirmed diagnosis HIV Insulin dependent diabetes mellitus / abnormal glucose tolerance test ( GTT ) / latent diabetes mellitus type I II Chemotherapy radiotherapy le 4 week prior entry Surgery less 2 week prior entry ( recovered effect surgery ) Participation clinical trial le 30 day prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Primary hepatocellular carcinoma</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>Tumour response</keyword>
	<keyword>Quality life</keyword>
</DOC>